Cargando…

Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients

Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lidenge, Salum J., Tso, For Yue, Mortazavi, Yasaman, Ngowi, John R., Shea, Danielle M., Mwaiselage, Julius, Wood, Charles, West, John T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352224/
https://www.ncbi.nlm.nih.gov/pubmed/32560243
http://dx.doi.org/10.3390/cancers12061594
_version_ 1783557587846823936
author Lidenge, Salum J.
Tso, For Yue
Mortazavi, Yasaman
Ngowi, John R.
Shea, Danielle M.
Mwaiselage, Julius
Wood, Charles
West, John T.
author_facet Lidenge, Salum J.
Tso, For Yue
Mortazavi, Yasaman
Ngowi, John R.
Shea, Danielle M.
Mwaiselage, Julius
Wood, Charles
West, John T.
author_sort Lidenge, Salum J.
collection PubMed
description Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05 were considered significant. Subjects with patch and plaque KS lesions responded more favorably to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants with KS despite a clinical KS response. While patch and plaque KS lesions were more common among treatment responders, none of the analyzed viral and immunological parameters distinguished responders from non-responders at baseline or after treatment.
format Online
Article
Text
id pubmed-7352224
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73522242020-07-21 Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients Lidenge, Salum J. Tso, For Yue Mortazavi, Yasaman Ngowi, John R. Shea, Danielle M. Mwaiselage, Julius Wood, Charles West, John T. Cancers (Basel) Article Kaposi’s sarcoma-associated herpes virus (KSHV) is the etiologic agent for Kaposi’s sarcoma (KS). The prognostic utility of KSHV and HIV-1 (human immunodeficiency virus) viremia as well as immunological parameters in clinical management of participants with KS is unclear. The objective of this study was to investigate viral and immunological parameters as predictors of KS treatment responses in participants with KS from sub-Saharan Africa (SSA). Plasma KSHV-DNA, HIV-1 viral load, total anti-KSHV antibody, KSHV-neutralizing antibody (nAb), cytokine/chemokine levels, and T-cell differentiation subsets were quantified before and after KS treatment in 13 participants with KS and in 13 KSHV-infected asymptomatic control individuals. One-way analysis of variance and the Mann-Whitney t-test were used to assess differences between groups where p-values < 0.05 were considered significant. Subjects with patch and plaque KS lesions responded more favorably to treatment than those with nodular lesions. Pre-treatment and post-treatment levels of plasma KSHV-DNA, HIV-1 viral load, KSHV-Ab responses, cytokines, and T-cell populations did not predict the KS treatment response. Elevated KSHV-humoral and cytokine responses persisted in participants with KS despite a clinical KS response. While patch and plaque KS lesions were more common among treatment responders, none of the analyzed viral and immunological parameters distinguished responders from non-responders at baseline or after treatment. MDPI 2020-06-16 /pmc/articles/PMC7352224/ /pubmed/32560243 http://dx.doi.org/10.3390/cancers12061594 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lidenge, Salum J.
Tso, For Yue
Mortazavi, Yasaman
Ngowi, John R.
Shea, Danielle M.
Mwaiselage, Julius
Wood, Charles
West, John T.
Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title_full Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title_fullStr Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title_full_unstemmed Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title_short Viral and Immunological Analytes are Poor Predictors of the Clinical Treatment Response in Kaposi’s Sarcoma Patients
title_sort viral and immunological analytes are poor predictors of the clinical treatment response in kaposi’s sarcoma patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352224/
https://www.ncbi.nlm.nih.gov/pubmed/32560243
http://dx.doi.org/10.3390/cancers12061594
work_keys_str_mv AT lidengesalumj viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT tsoforyue viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT mortazaviyasaman viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT ngowijohnr viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT sheadaniellem viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT mwaiselagejulius viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT woodcharles viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients
AT westjohnt viralandimmunologicalanalytesarepoorpredictorsoftheclinicaltreatmentresponseinkaposissarcomapatients